Tardive Dyskinesia Therapeutics Market Report 2026

The tardive dyskinesia therapeutics market size has grown strongly in recent years. It will grow from $3.12 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to limited treatment options for tardive dyskinesia, reliance on conventional antipsychotic management, low patient awareness, growing prevalence of antipsychotic use, restricted specialty treatment centers.

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to development of novel therapeutics for tardive dyskinesia, increased r&d investment in neurological disorders, rising preference for homecare settings, expansion of specialty treatment centers, enhanced patient monitoring and digital therapeutics. Major trends in the forecast period include rising adoption of deutetrabenazine and valbenazine, increased focus on personalized neurological therapy, expansion of homecare and remote treatment options, growing awareness about drug-induced tardive dyskinesia, emphasis on safety and compliance in long-term treatment.

The rising prevalence of mental health disorders is anticipated to drive the growth of the tardive dyskinesia therapeutics market in the coming years. Mental health disorders are conditions that impact an individual’s thoughts, emotions, behavior, or overall functioning, often leading to significant distress or challenges in everyday life. The increase in mental health disorders is largely attributed to growing social isolation, as greater reliance on digital communication and fast-paced lifestyles has reduced meaningful face-to-face interactions, resulting in heightened feelings of loneliness and emotional stress. Tardive dyskinesia therapeutics assist patients with mental disorders by managing involuntary movement symptoms associated with long-term antipsychotic use, thereby supporting treatment adherence and improving overall quality of life. For instance, in 2024, according to the National Alliance on Mental Illness, a US-based organization, psychosis spectrum and mood disorders accounted for nearly 600,000 hospitalizations annually among individuals in the U.S. aged 18 to 44. Therefore, the increasing prevalence of mental health disorders is driving the growth of the tardive dyskinesia therapeutics market.

Major companies operating in the tardive dyskinesia therapeutics market are concentrating on developing advanced products, such as once-daily treatment options, to ensure more consistent drug levels in the body. Once-daily treatment options are therapies designed to be administered a single time each day, simplifying dosing regimens and enhancing patient compliance. For example, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved AUSTEDO XR tablets for the treatment of adults with tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. The approval of AUSTEDO XR provides patients with proven efficacy in controlling involuntary movements along with the convenience of a once-daily, single-tablet regimen. This formulation delivers clinically effective doses validated through pivotal clinical trials and is available in four tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

In February 2024, Teva Pharmaceutical Industries Limited partnered with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute Teva’s AUSTEDO. Through this collaboration, the companies aim to expand patient access to AUSTEDO by leveraging Nhwa’s strong presence in China’s neuropsychiatric healthcare market. AUSTEDO is recognized as the first vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a China-based pharmaceutical company.

Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.

North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tardive dyskinesia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the tardive dyskinesia therapeutics market by increasing costs for imported active pharmaceutical ingredients and formulation equipment. Segments such as tablets, capsules, and injectable dosage forms are particularly affected, with North American and Asia-Pacific regions facing notable import duties. This has led to higher production costs and potential delays in drug availability. On the positive side, tariffs encourage local manufacturing, innovation in cost-effective drug development, and diversification of supply chains.

The tardive dyskinesia therapeutics market research report is one of a series of new reports that provides tardive dyskinesia therapeutics market statistics, including tardive dyskinesia therapeutics industry global market size, regional shares, competitors with a tardive dyskinesia therapeutics market share, detailed tardive dyskinesia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. This tardive dyskinesia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tardive dyskinesia therapeutics encompass treatments developed to manage or reduce the involuntary, repetitive movements associated with this neurological condition. These therapies are designed to address underlying neurological imbalances, which are often linked to the long-term use of certain medications. The primary objective is to enhance patient quality of life by decreasing the severity and frequency of motor symptoms, improving functional capabilities, and limiting long-term complications.

The main drugs used in tardive dyskinesia therapeutics include deutetrabenazine, valbenazine, and others. Deutetrabenazine is a vesicular monoamine transporter type 2 (VMAT2) inhibitor prescribed to treat involuntary movements related to tardive dyskinesia. It is available in various product forms, including solid dosage forms such as tablets and capsules, as well as liquid formulations and injections. Deutetrabenazine is used for indications including antipsychotic-induced tardive dyskinesia, other drug-induced tardive dyskinesia, and idiopathic tardive dyskinesia. These therapies are utilized by end users such as hospitals, clinics, specialty treatment centers, and homecare settings.

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.